Hansoh Pharma's Osteosarcoma Therapy Gains NMPA Priority Review Designation

Stock News09-22 17:06

Hansoh Pharma (03692) has announced that its product, HS-20093 (Rezenvaninab vedotin for injection), has been accepted into the priority review and approval process by China's National Medical Products Administration (NMPA) for the treatment of osteosarcoma.

According to the company's announcement dated September 14, 2026, this designation is based on the positive results of the pivotal Phase III trial ARTEMIS-011. The indication covers patients aged 12 years and older with osteosarcoma who have failed at least two prior lines of therapy.

The inclusion in the priority review program is expected to expedite the regulatory review process for this potentially important treatment option in an area of high unmet medical need.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1101889814?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-22 17:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1101889814","market":"sh","top_or_hot":-1,"title":"Hansoh Pharma's Osteosarcoma Therapy Gains NMPA Priority Review Designation","media":"Stock News","content":"<p><b>Hansoh Pharma</b> (03692) has announced that its product, HS-20093 (Rezenvaninab vedotin for injection), has been accepted into the priority review and approval process by China's National Medical Products Administration (NMPA) for the treatment of osteosarcoma.<br><br>According to the company's announcement dated September 14, 2026, this designation is based on the positive results of the pivotal Phase III trial ARTEMIS-011. The indication covers patients aged 12 years and older with osteosarcoma who have failed at least two prior lines of therapy.<br><br>The inclusion in the priority review program is expected to expedite the regulatory review process for this potentially important treatment option in an area of high unmet medical need.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hansoh Pharma's Osteosarcoma Therapy Gains NMPA Priority Review Designation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHansoh Pharma's Osteosarcoma Therapy Gains NMPA Priority Review Designation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-22 17:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Hansoh Pharma</b> (03692) has announced that its product, HS-20093 (Rezenvaninab vedotin for injection), has been accepted into the priority review and approval process by China's National Medical Products Administration (NMPA) for the treatment of osteosarcoma.<br><br>According to the company's announcement dated September 14, 2026, this designation is based on the positive results of the pivotal Phase III trial ARTEMIS-011. The indication covers patients aged 12 years and older with osteosarcoma who have failed at least two prior lines of therapy.<br><br>The inclusion in the priority review program is expected to expedite the regulatory review process for this potentially important treatment option in an area of high unmet medical need.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1589","symbol_name":"北水核心资产","start_time":0,"source_url":"","article_id":"1101889814","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1101889814","pubTimestamp":1790067974,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Hansoh Pharma (03692) has announced that its product, HS-20093 (Rezenvaninab vedotin for injection), has been accepted into the priority review and approval process by China's National Medical...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1589":"北水核心资产","BK1191":"制药","BK1583":"高瓴概念","03692":"翰森制药"},"translate_title":"豪森制药骨肉瘤疗法获NMPA优先审评资格","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":1},"content_text":"Hansoh Pharma (03692) has announced that its product, HS-20093 (Rezenvaninab vedotin for injection), has been accepted into the priority review and approval process by China's National Medical Products Administration (NMPA) for the treatment of osteosarcoma.According to the company's announcement dated September 14, 2026, this designation is based on the positive results of the pivotal Phase III trial ARTEMIS-011. The indication covers patients aged 12 years and older with osteosarcoma who have failed at least two prior lines of therapy.The inclusion in the priority review program is expected to expedite the regulatory review process for this potentially important treatment option in an area of high unmet medical need.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1101889814","isCrawlerRequest":true}